DGX

Quest Diagnostics Incorporated

Healthcare
US companies in Healthcare (47)
NYSE · USD
Mkt cap $26.8bn

$242.56

as of 27 Oct 2026, 3% below its 52-week high

Screens as well placed to keep growing its dividend, with low cut-risk signals. Its valuation looks somewhat extended against its own history.

These scores are a resilience check on the dividend, not a recommendation to buy or sell. They are not financial advice.

Trailing yield: 1.39%Last 12 months of regular payments at today's price
Forward yield: 1.49%Each payment expected in the next 12 months, not the latest one doubled
Earnings cover: 3.1×Pays 33% of earnings
Cash cover: 3.7×Free cash flow over dividends paid
5y dividend growth: +7.3% a yearLast cut in FY2023
Next ex-dividend date: Estimated13 Jan 2027Quarterly dividend of about $0.85

Compared with US companies in Healthcare (47)

Trailing yield is higher than 29 of the 46 other US companies in Healthcare.
5y dividend growth (as paid) is higher than 22 of the 38 other US companies in Healthcare with a 5y growth figure.

Quality

High

Capacity to keep growing the dividend

Risk

Low

Signals of dividend-cut pressure

Trim

Moderate

How extended the valuation looks

Why Trim is 67

DGX against US companies in Healthcare (47)

Valuation against its own history

As of the last reported period (30 Sept 2026). P80 means the figure is higher than 80% of DGX’s past readings.

P/E22.7×P100, poor for this measure
Yield1.42%P2, poor for this measure
FCF payout26.8%P36, neutral for this measure
Net debt / EBITDA2.38P32, neutral for this measure
DGR 5y+7.1%P11, poor for this measure
ROIC8.8%P59, neutral for this measure

Open valuation history

Forecast your income with the DGX dividend calculator

Inspect surfaces history; it does not predict the future. Nothing here is financial advice or an instruction to buy or sell. Always do your own research. See the Terms of Service.